Karyopharm Therapeutics | Nettoeinkommen

Aktienkurs
6.46
Täglich Wechseln
-0.14 -2.05%
Monatlich
-21.23%
Jährlich
-26.54%
Q1 Prognose
1.30




Nettoeinkommen Veränderung Datum
AbbVie USD 1.82B 1.63B 2025-12
Abbott USD 1.78B 132M 2025-12
Amgen USD 1.33B 1.88B 2025-12
AstraZeneca USD 2.33B 207M 2025-12
BioCryst Pharmaceuticals USD -88.88M 74.85M 2024-12
Bristol-Myers Squibb USD 1.09B 1.11B 2025-12
Eli Lilly USD 6.64B 1.05B 2025-12
Enanta Pharmaceuticals USD -22.29M 93.76M 2024-12
GlaxoSmithKline GBP 636M 1.38B 2025-12
Incyte USD 299.28M 124.89M 2025-12
J&J USD 5.12B 36M 2025-12
Karyopharm Therapeutics USD -30.78M 1.29M 2024-12
MacroGenics USD 16.82M 53.07M 2025-09
Merck USD 2.96B 2.82B 2025-12
Nektar Therapeutics USD -37.06M 15.31M 2024-09
Novartis USD 3.93B 96M 2025-09
Novartis USD 3.93B 113M 2025-09
Pfizer USD -1.65B 5.19B 2025-12
Regeneron Pharmaceuticals USD 844.6M 615.4M 2025-12
Roche Holding CHF 5.47B 1.76B 2025-12
Sangamo BioSciences USD -36.13M 12.96M 2024-06
Takeda JPY 103.64B 115.44B 2025-12
Tectonic Therapeutic USD -19.04M 940K 2025-09
TG Therapeutics USD 390.9M 362.71M 2025-09
Ultragenyx Pharmaceutical USD -180.41M 65.46M 2025-09
Xencor USD -6.03M 24.8M 2025-09


Karyopharm Therapeutics Nettoeinkommen - Diese Werte, historische Daten, Prognosen, Statistiken, Diagramme und ökonomische Kalender - Feb 2026.